Christophe Mellon

Christophe Mellon is an experienced leader in the pharmaceutical and biotechnology sectors, currently serving as Vice-President CMC at Neurenati Therapeutics since January 2025, overseeing formulation efforts and CMC production of GDNF protein in Europe. Previously, Christophe held the role of Chief Executive Officer at giiant pharma inc., where leadership focused on leveraging science for the benefits of investors and patients, and also served as Vice President of Discovery & Chemistry. Additional roles include General Manager at MIRAPAKON, Project Manager RnD at SiliCycle Inc., Associate Director at OmegaChem and Thallion Pharmaceuticals, and Research Fellow at Merck. Christophe's academic credentials include a PostDoc in Organic Chemistry from the Massachusetts Institute of Technology, a Ph.D. in Organic Chemistry from Université de Montréal, and a Bachelor of Science in Chemistry from Université Laval.